Search

Your search keyword '"Cobo, M."' showing total 1,107 results

Search Constraints

Start Over You searched for: Author "Cobo, M." Remove constraint Author: "Cobo, M."
1,107 results on '"Cobo, M."'

Search Results

1. Designing and Evaluating Personalized Learning Itineraries: An Experience at the University

6. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

7. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

10. TTFields (Tumor Treating Fields) associés au traitement standard dans les cancers du poumon non à petites cellules métastatiques en progression après platine : étude internationale, randomisée de phase 3 LUNAR

11. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

14. EP08.03-01 Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials

15. OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study

16. MA03.11 Big Data and Artificial Intelligence for Exploring the Role of Genetic Risk. Family History of Cancer and Lung Cancer. Results from CLARIFY

17. P1.21-02 Genetic Susceptibility to Immune Checkpoints Blockade Resistance

18. P1.01-04 Clinical and Genetic Characteristics in Younger vs Older Lung Cancer Patients

19. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

20. P2.05-13 Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1

21. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

22. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

25. Visualization and Evolution of the Scientific Structure of Fuzzy Sets Research in Spain

26. Measuring the Impact of the International Relationships of the Andalusian Universities Using Dimensions Database

27. Constructing Bibliometric Networks from Spanish Doctoral Theses

28. Cantor Singular Continuous Spectrum for Operators Along Interval Exchange Transformations

29. Factores asociados al ataque cerebrovascular isquémico entre los años 2013 a 2016: estudio de casos y controles

33. Principles and orientations for media users’ ethics: contributions from the side of the Catholic Church’s Social Teaching

34. Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity

41. 22 Years of Lean Supply Chain Management: a science mapping-based bibliometric analysis.

43. A consensus statement on the gender perspective in lung cancer

44. Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy

45. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

49. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

50. P1.15-09 First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study.

Catalog

Books, media, physical & digital resources